Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C28H28N4O3 · HCl
Número CAS:
Peso molecular:
505.01
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Storage condition:
desiccated, protect from light
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleQuality Level
assay
≥98% (HPLC)
form
powder
storage condition
desiccated, protect from light
color
orange-red
solubility
DMSO: 10 mg/mL, clear
storage temp.
−20°C
SMILES string
Cl.[n]21c3c(c(c2)C4=C(c5c6c([n](c5)CC[C@H](OCC1)CN(C)C)cccc6)C(=O)NC4=O)cccc3
InChI
1S/C28H28N4O3.ClH/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24;/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34);1H/t18-;/m0./s1
InChI key
NYQIEYDJYFVLPO-FERBBOLQSA-N
General description
LY-333531 hydrochloride is also known as ruboxistaurin.
Application
LY-333531 hydrochloride/ruboxistaurin has been used as a PKCB blocker to compare phosphopeptides derived from stimulated wild-type cells to phosphopeptides derived from either PKCB knockout cells or wild-type cells.
Biochem/physiol Actions
LY333531 is a potent inhibitor of protein kinase Cβ (PKCβ; 4.7 and 5.9 nM IC50 values for PKCβ1 and PKCβ2, respectively). PKCβ isoforms are overexpressed in states of oxidative stress, especially in association with diabetes. In diabetic rats, LY333531 improves blood flow and leukocyte entrapment in the retina, and protects against myocardial hypertrophy and cardiac dysfunction.
LY333531 is a potent, specific inhibitor of PKCβ.
Features and Benefits
This compound is featured on the PKC page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Other Notes
Light sensitive
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain.
Rimessi A, et al.
Neuropsychopharmacology, 42(7), 1491?1501-1491?1501 (2017)
Phosphorylation of residues inside the SNARE complex suppresses secretory vesicle fusion.
Malmersjo S, et al.
The Embo Journal, e201694071-e201694071 (2016)
Hongwei Yi et al.
Antioxidants & redox signaling, 30(17), 1949-1968 (2018-11-30)
Aims: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver diseases. However, there are no approved pharmacotherapies for the treatment of NAFLD other than managing life style and controlling diets. Extensive studies have demonstrated that multiple